In Phase I and Phase II development, pharmaceutical teams need to make critical decisions with limited information.

Is the drug producing the expected biological effect? Is that effect increasing with dose? Which patients are responding (and why)? Are higher exposure levels producing additional benefit or simply adding biological stress? Can an early molecular signal help explain what may happen later in the trial?

Pharmacokinetics can show how much drug reaches the bloodstream. Clinical endpoints can eventually show whether patients improve. But there is often an important gap between the two:

How is the patient’s biology actually responding to the treatment?

BASE4 Biosciences is building a new layer of pharmacodynamic intelligence to help answer this question.

Using longitudinal blood samples, transcriptomic data and sex-specific computational models, BASE4 can analyse how an individual’s biological state changes before and after treatment. The objective is to provide pharmaceutical teams with a deeper view of dose response, patient heterogeneity and the molecular mechanisms associated with treatment.

From drug exposure to biological response

Two patients can receive the same dose and show similar drug exposure while experiencing very different biological and clinical responses.

One may activate the expected therapeutic pathways. Another may show a weak response. A third may develop compensatory or unexpected molecular changes.

Traditional biomarkers are essential, but they often focus on a limited number of predefined targets. BASE4 adds a broader systems-level view by analysing changes across genes and biological pathways.

This allows drug-development teams to investigate:

Whether treatment is generating a measurable biological response.

Whether that response changes according to dose or exposure.

Whether the desired biological effect reaches a plateau.

Which patients show strong, weak or atypical responses.

Which genes and pathways may explain those differences.

Whether relevant differences appear between female and male participants.

The Strategic Framework developed for BASE4 defines this opportunity clearly: the platform’s strongest initial pharmaceutical application is not simply estimating biological state, but measuring how that state changes in response to a disease or intervention, including dose-dependent effects.

Longitudinal analysis at the individual level

BASE4 is designed to analyse biological change within each patient.

By comparing a baseline blood sample with samples collected during and after treatment, the platform can reconstruct an individual response trajectory.

This helps determine:

How much a patient’s biology has changed.

How quickly the response appears.

Whether the change becomes stronger with continued exposure.

Whether it remains stable, increases or returns towards baseline.

Whether patients receiving the same dose follow different biological trajectories.

This longitudinal approach is especially relevant in early clinical development, where average treatment-group results can hide substantial biological heterogeneity.

Rather than asking only whether a group improved on average, BASE4 helps explore a more precise question:

What happened biologically in each patient after receiving the drug?

Supporting dose and proof-of-concept decisions

Dose selection remains one of the most consequential decisions in drug development.

A higher dose may generate more systemic exposure, but that does not always translate into a proportionally greater biological effect. In some cases, the expected response may plateau, while additional pathways begin to show unwanted perturbation.

By integrating BASE4 outputs with dose, pharmacokinetic exposure and conventional trial endpoints, pharmaceutical teams can explore:

Whether increasing exposure produces a stronger biological response.

Whether a minimum biologically active dose can be identified.

Whether the desired response reaches a plateau.

Whether higher doses introduce additional or unexpected biological effects.

Whether similar exposure produces different responses across patients.

BASE4 does not replace PK, clinical pharmacology or established biomarkers. It complements them by adding the patient’s broader molecular response.

A useful framework is:

Dose → Drug exposure → Biological response → Clinical outcome

BASE4 is focused on making the biological-response layer more visible.

Understanding responders and non-responders

A central challenge in Phase II is understanding why some patients benefit while others do not.

BASE4 can compare the longitudinal molecular profiles of responders and non-responders to investigate:

Differences in baseline biological state.

Early pathways associated with later response.

Mechanisms linked to weak or absent response.

Compensatory biological activity.

Molecular patterns associated with intolerance or adverse outcomes.

Potential subgroups for future development.

This can help translational and precision-medicine teams move beyond a binary classification of response and investigate the underlying biology.

The output is not only a composite score. BASE4 can provide a mechanistic layer identifying the genes and pathways that contribute to the observed change, helping teams assess whether the response is consistent with the drug’s intended mechanism of action.

Sex-specific biological modelling

Female and male biology can regulate genes and pathways differently across tissues and clinical contexts.

BASE4 incorporates sex-specific models rather than applying the same universal biological reference to every participant.

For pharmaceutical development, this supports:

Separate interpretation of molecular response in women and men.

Analysis of treatment response within each sex.

Identification of sex-associated biological patterns.

More representative evaluation of patient heterogeneity.

Generation of evidence for future sex-aware clinical strategies.

This is particularly relevant when treatments may produce different pharmacological, immune, metabolic or safety profiles across female and male populations.

Designed to work with existing clinical-trial samples

Pharmaceutical companies can begin working with BASE4 without immediately changing an ongoing clinical programme.

A first collaboration can use existing longitudinal blood samples or available RNA-sequencing data from a completed or ongoing Phase I or Phase II study.

An initial BASE4 Retrospective Pharmacodynamic Pilot can investigate a predefined question such as:

Does the molecular response increase with dose?

Can BASE4 distinguish biological responders from non-responders?

Is an early change associated with a later clinical endpoint?

Which pathways explain the observed treatment response?

Does BASE4 add information beyond conventional biomarkers?

Are there relevant differences between female and male participants?

A typical project can include:

Baseline and post-treatment samples.

Different doses or exposure levels.

Pharmacokinetic data, where available.

Clinical response, disease-activity or safety information.

Conventional biomarkers for comparison.

BASE4 can then deliver:

Individual biological change from baseline.

Dose- and exposure–response analyses.

Responder and non-responder characterisation.

Comparison with existing biomarkers.

Sex-specific results.

Gene- and pathway-level interpretation.

A clear assessment of whether prospective evaluation is justified.

The Strategic Framework recommends precisely this type of collaboration: a pre-specified retrospective study using existing longitudinal samples to determine whether BASE4 captures dose-dependent biological response and provides information beyond conventional biomarkers.

Where BASE4 can provide the greatest value

BASE4 is particularly suited to early clinical programmes with:

Multiple dose levels.

Longitudinal blood samples.

High patient heterogeneity.

Slow, variable or difficult-to-interpret clinical endpoints.

Limited pharmacodynamic biomarkers.

Systemic mechanisms of action.

A need to understand non-response.

Important biological differences between women and men.

Potential applications include immunology, inflammatory and autoimmune diseases, oncology, metabolic conditions and other programmes where treatment can generate systemic biological effects.

A practical new layer for drug development

The value of BASE4 is not simply generating more molecular data.

It is helping pharmaceutical teams convert longitudinal blood samples into answers that can support real development decisions:

Is the drug biologically active?

Is the response dose-dependent?

Is there evidence of a plateau?

Which patients respond differently?

Which mechanisms explain those differences?

Does the molecular response add information beyond existing endpoints?

Should the biomarker be included prospectively in the next trial?

BASE4 combines genomic and transcriptomic science, sex-specific modelling and longitudinal patient analysis to help make drug response more measurable and interpretable.

For pharmaceutical teams working in Phase I and Phase II, this creates a practical opportunity: start with existing samples, test a clearly defined hypothesis and determine whether BASE4 can add a new layer of evidence to the programme.

BASE4 helps reveal not only whether a drug reaches the patient, but how the patient’s biology responds to it.